国药现代
(600420)
| 流通市值：138.27亿 | | | 总市值：138.27亿 |
| 流通股本：13.41亿 | | | 总股本：13.41亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,606,778,071.34 | 10,937,525,114.43 | 8,593,322,350.59 | 5,960,093,922.86 |
| 营业收入 | 2,606,778,071.34 | 10,937,525,114.43 | 8,593,322,350.59 | 5,960,093,922.86 |
| 二、营业总成本 | 2,109,040,170.15 | 9,209,243,716.28 | 7,149,548,193.4 | 4,938,858,986.31 |
| 营业成本 | 1,639,786,034.72 | 6,645,214,332.76 | 5,182,776,783.47 | 3,598,033,483.09 |
| 税金及附加 | 25,434,133.06 | 131,545,473.11 | 91,849,830.17 | 67,551,190.03 |
| 销售费用 | 182,917,156.79 | 1,151,961,230.5 | 969,120,997.86 | 716,477,575.38 |
| 管理费用 | 170,297,645.51 | 793,272,889.94 | 556,786,615.94 | 373,755,281.67 |
| 研发费用 | 110,732,450.33 | 575,929,683.34 | 416,208,957.38 | 244,601,026.49 |
| 财务费用 | -20,127,250.26 | -88,679,893.37 | -67,194,991.42 | -61,559,570.35 |
| 其中:利息费用 | 1,406,133.14 | 36,887,575.36 | 27,837,847.97 | 18,697,936.94 |
| 其中:利息收入 | 14,281,492.31 | 86,969,890.14 | 74,174,042.98 | 54,380,605.68 |
| 加:投资收益 | 20,681,510.13 | 64,105,907.49 | 36,495,743.56 | 16,838,682.09 |
| 资产处置收益 | -451,811.48 | -31,310,025.43 | -5,493,372.69 | -2,049,581.83 |
| 资产减值损失(新) | -19,213,632.51 | -168,498,777.81 | -93,834,179.46 | -11,308,517.94 |
| 信用减值损失(新) | -11,497,455.74 | 2,355,979.98 | -4,009,663.05 | -3,597,539.2 |
| 其他收益 | 21,799,967.01 | 156,989,031.04 | 91,439,320.66 | 75,586,044.01 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 509,056,478.6 | 1,751,923,513.42 | 1,468,372,006.21 | 1,096,704,023.68 |
| 加:营业外收入 | 6,258,395.12 | 15,259,934.4 | 10,042,756.13 | 7,749,451.45 |
| 减:营业外支出 | 4,268,114.13 | 94,129,610.68 | 21,724,505.36 | 18,051,572.89 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 511,046,759.59 | 1,673,053,837.14 | 1,456,690,256.98 | 1,086,401,902.24 |
| 减:所得税费用 | 87,507,012.67 | 340,974,126.89 | 257,243,613.37 | 199,514,176.61 |
| 六、净利润 | 423,539,746.92 | 1,332,079,710.25 | 1,199,446,643.61 | 886,887,725.63 |
| 持续经营净利润 | 423,539,746.92 | 1,332,079,710.25 | 1,199,446,643.61 | 886,887,725.63 |
| 归属于母公司股东的净利润 | 361,413,759.19 | 1,083,622,881.88 | 954,526,387.18 | 718,477,263.45 |
| 少数股东损益 | 62,125,987.73 | 248,456,828.37 | 244,920,256.43 | 168,410,462.18 |
| (一)基本每股收益 | 0.27 | 0.81 | 0.71 | 0.54 |
| (二)稀释每股收益 | 0.27 | 0.81 | 0.71 | 0.54 |
| 八、其他综合收益 | - | 174,838.86 | -111,674.09 | -111,674.09 |
| 归属于母公司股东的其他综合收益 | - | 174,838.86 | -111,674.09 | -111,674.09 |
| 九、综合收益总额 | 423,539,746.92 | 1,332,254,549.11 | 1,199,334,969.52 | 886,776,051.54 |
| 归属于母公司股东的综合收益总额 | 361,413,759.19 | 1,083,797,720.74 | 954,414,713.09 | 718,365,589.36 |
| 归属于少数股东的综合收益总额 | 62,125,987.73 | 248,456,828.37 | 244,920,256.43 | 168,410,462.18 |
| 公告日期 | 2025-04-29 | 2025-03-28 | 2024-10-29 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |